These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38878009)

  • 1. Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics.
    Kosiborod MN; Cherney D; Connelly K; Desai AS; Guimarães PO; Kuthi L; Lala A; Madrini V; Merkely B; Villota JN; Squire I; Testani JM; Vaclavik J; Verma S; Wranicz J; Dahl M; Eudicone JM; Friberg L; Petrie MC
    JACC Heart Fail; 2024 May; ():. PubMed ID: 38878009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HARMONIZE Asia: A Phase III Randomized Study to Investigate the Efficacy and Safety of Sodium Zirconium Cyclosilicate in Patients with Hyperkalemia in China.
    Liang X; Lu W; Yu X; Cheng H; He Q; Peng Q; Ni Z; Long G; Wang L; Chen W; Li R; Zhao J; Zhang Y; Lisovskaja V; Tang Z
    Clin Ther; 2024 Sep; 46(9):702-710. PubMed ID: 39112102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients.
    Ni Z; Lu R; Xu X; Bian X; Zhou Z; Yang J; Luo Q; Chen M; Chen C; Sun X; Yu L; He Q; Jiang H; Yuan W; Li Y; Zhou R; Wang J; Zhang X; Zuo L; Meng X; Chang Z; Zhao J; Wessman P; Xiang P;
    Clin Ther; 2023 Jul; 45(7):633-642. PubMed ID: 37385905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
    Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
    JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study.
    Ash SR; Batlle D; Kendrick J; Oluwatosin Y; Pottorf W; Brahmbhatt Y; Guerrieri E; Fried L
    Nephron; 2022; 146(6):599-609. PubMed ID: 35462371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
    Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N
    Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
    Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure.
    Tardif JC; Rouleau J; Chertow GM; Al-Shurbaji A; Lisovskaja V; Gustavson S; Zhao Y; Bouabdallaoui N; Desai AS; Chernyavskiy A; Evsina M; Merkely B; McMurray JJV; Pfeffer MA
    ESC Heart Fail; 2023 Apr; 10(2):1066-1076. PubMed ID: 36564955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum potassium response to single-dose sodium zirconium cyclosilicate for the treatment of asymptomatic hyperkalemia in hospitalized patients.
    Lewis H; Stamper B; Yungkurth AC
    Pharmacotherapy; 2024 Jan; 44(1):13-21. PubMed ID: 37475499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure.
    Imamura T; Narang N; Kinugawa K
    J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36142977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease.
    Burton JO; Allum AM; Amin A; Linde C; Lesén E; Mellström C; Eudicone JM; Sood MM
    Clin Kidney J; 2023 Jul; 16(7):1160-1169. PubMed ID: 37398685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single Dose of Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate in Hospitalized Patients With Hyperkalemia.
    Yoo N; Song YB; Dubinsky I; Altshuler J
    Ann Pharmacother; 2023 Sep; 57(9):1044-1052. PubMed ID: 36637028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Experience of Hyperkalemia Management Using Sodium Zirconium Cyclosilicate in Chronic Hemodialysis: A Multicenter Clinical Audit.
    Qu X; Hua Y; Khan BA
    Cureus; 2023 Sep; 15(9):e45058. PubMed ID: 37829953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia.
    Imamura T; Oshima A; Narang N; Kinugawa K
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
    Shen L; Kristensen SL; Bengtsson O; Böhm M; de Boer RA; Docherty KF; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez MFA; O'Meara E; Nicolau JC; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV
    JACC Heart Fail; 2021 Apr; 9(4):254-264. PubMed ID: 33549554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.